Clopidogrel / Acetylsalicylic acid Mylan

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
17-01-2024
Tabia za bidhaa Tabia za bidhaa (SPC)
17-01-2024

Viambatanisho vya kazi:

Acetylsalicylic acid, clopidogrel hydrogen sulfate

Inapatikana kutoka:

Mylan Pharmaceuticals Limited

ATC kanuni:

B01AC30

INN (Jina la Kimataifa):

clopidogrel, acetylsalicylic acid

Kundi la matibabu:

Antithrombotic agents

Eneo la matibabu:

Acute Coronary Syndrome; Myocardial Infarction

Matibabu dalili:

Clopidogrel/Acetylsalicylic acid Mylan is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA).Clopidogrel/Acetylsalicylic acid Mylan is a fixed-dose combination medicinal product for continuation of therapy in:Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary interventionST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy

Bidhaa muhtasari:

Revision: 5

Idhini hali ya:

Authorised

Idhini ya tarehe:

2020-01-09

Taarifa za kipeperushi

                                44
B. PACKAGE LEAFLET
45
Package leaflet: Information for the patient
Clopidogrel/Acetylsalicylic acid Viatris 75 mg/75 mg film-coated
tablets
Clopidogrel/Acetylsalicylic acid Viatris 75 mg/100 mg film-coated
tablets
clopidogrel/acetylsalicylic acid
Read all of this leaflet carefully before you start taking this
medicine because it contains
important information for you.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
What is in this leaflet
1.
What Clopidogrel/Acetylsalicylic acid Viatris is and what it is used
for
2.
What you need to know before you take Clopidogrel/Acetylsalicylic acid
Viatris
3.
How to take Clopidogrel/Acetylsalicylic acid Viatris
4.
Possible side effects
5.
How to store Clopidogrel/Acetylsalicylic acid Viatris
6.
Contents of the pack and other information
1. What Clopidogrel/Acetylsalicylic acid Viatris is and what it is
used for
Clopidogrel/Acetylsalicylic acid Viatris contains clopidogrel and
acetylsalicylic acid (ASA) and
belongs to a group of medicines called antiplatelet medicinal
products. Platelets are very small
structures in the blood which clump together during blood clotting. By
preventing this clumping in
some types of blood vessels (called arteries), antiplatelet medicinal
products reduce the chances of
blood clots forming (a process called atherothrombosis).
Clopidogrel/Acetylsalicylic acid Viatris is taken by adults to prevent
blood clots forming in hardened
arteries which can lead to atherothrombotic events (such as stroke,
heart attack, or death).
You have been prescribed Clopidogrel/Acetylsalicylic acid Viatris in
place of the two separate
medicines, clopidogrel and ASA, to help prevent blood clots because

                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Clopidogrel/Acetylsalicylic acid Viatris 75 mg/75 mg film-coated
tablets
Clopidogrel/Acetylsalicylic acid Viatris 75 mg/100 mg film-coated
tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Clopidogrel/Acetylsalicylic acid Viatris 75 mg/75 mg film-coated
tablets
Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen
sulphate) and 75 mg of
acetylsalicylic acid (ASA).
Excipients with known effect
Each film-coated tablet contains 48 mg of lactose.
Clopidogrel/Acetylsalicylic acid Viatris 75 mg/100 mg film-coated
tablets
Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen
sulphate) and 100 mg of
acetylsalicylic acid (ASA).
Excipients with known effect
Each film-coated tablet contains 48 mg of lactose and 0.81 mg Allura
Red AC.
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Film coated tablet (tablet)
Clopidogrel/Acetylsalicylic acid Viatris 75 mg/75 mg film-coated
tablets
Yellow, oval shaped, biconvex, film-coated tablets, approximately 14.5
mm x 7.4 mm debossed with
“CA2” on one side of the tablet and “M” on the other side.
Clopidogrel/Acetylsalicylic acid Viatris 75 mg/100 mg film-coated
tablets
Pink, oval shaped, biconvex, film-coated tablets, approximately 14.8
mm x 7.8 mm debossed with
“CA3” on one side of the tablet and “M” on the other side.
4.
CLINICAL PARTICULARS
4.1
Therapeutic indications
Clopidogrel/Acetylsalicylic acid Viatris is indicated for the
secondary prevention of atherothrombotic
events in adult patients already taking both clopidogrel and
acetylsalicylic acid (ASA).
Clopidogrel/Acetylsalicylic acid Viatris is a fixed-dose combination
medicinal product for
continuation of therapy in:
•
Non-ST segment elevation acute coronary syndrome (unstable angina or
non-Q-wave
myocardial infarction) including patients undergoing a stent placement
following percutaneous
coronary intervention (PCI)
3
•
ST segment elevation acute myocardial infarction (STEMI) in
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kibulgaria 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kihispania 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kicheki 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kidenmaki 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kijerumani 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kiestonia 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kigiriki 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kifaransa 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kiitaliano 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kilatvia 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kilithuania 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kihungari 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kimalta 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kiholanzi 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kipolandi 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kireno 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kiromania 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kislovakia 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kislovenia 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kifinlandi 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kiswidi 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 24-01-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kinorwe 17-01-2024
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 17-01-2024
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 17-01-2024
Tabia za bidhaa Tabia za bidhaa Kroeshia 17-01-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 24-01-2020